Collaborations

Agreement signed between Ipsen and MSD to comarket Adrovance

Published in Medical Device Law Weekly, March 4th, 2007

Ipsen and MSD announced the signing of a comarketing agreement under which MSD will grant Ipsen the marketing rights in France for Adrovance, a fixed combination of alendronate sodium and cholecalciferol (vitamin D3), indicated for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D deficiency.

Adrovance reduces the risk of vertebral and hip fractures. MSD currently markets this product under the brand name Fosavance.

Under the terms of the agreement, Ipsen will source the product from MSD, market and sell it under the brand name Adrovance in France.

Christophe Jean, executive VP, chief operations officer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Law Weekly

Source: Medical Device Law Weekly (2007-03-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry